Pill forms of Wegovy don't require refrigeration
This list reflects publicly available information as of June 2026
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Additionally, their antitumour functions have been shown to stimulate an adaptive immune response and secrete cytotoxic mediators to render tumour cells more susceptible [187, 188]
Considering the distribution of GLP-1 receptors (GLP-1R) in brain regions associated with mood regulation (Sharma et al
This remains Eli Lillys most versatile titration for those who plateau at lower amounts
